Evonik stock faces a more cautious 2027 earnings outlook

Evonik entered the second half of November with a more cautious earnings view and a product showcase in Specialty Nutrition. Jefferies downgraded the specialty chemicals maker to Hold from Buy on November 11, while Evonik presented new nutrition solutions at EuroTier in Hanover from November 10 to 13.

Jefferies trims the earnings outlook

According to Investing.com, Jefferies cut its 2027 EBITDA forecast by 9% to below 2 billion euros. The brokerage raised its price target to 21 euros from 20 euros but said fading supply disruption support and uncertainty around potential engagement with BASF had changed the near-term setup.

Jefferies also questioned whether Evonik can reach its 11% return on capital employed target by 2029. Its forecast was 8.9%, assuming operating profit improvements and lower capital employed. Fourth-quarter results and 2027 guidance are scheduled for March 4, 2027.

Specialty Nutrition remains strategic

At EuroTier, Evonik highlighted its MetAMINO products and introduced Lypron and ZyneXtra. The company said the solutions are designed to support more efficient animal nutrition, while the exhibition in Hanover ran from November 10 through November 13, according to Evonik.

Evonik stock traded at 21.16 euros on Lang & Schwarz at 12:00:49 CET on Saturday, November 14, 2026.

German equity conditions remain relevant for Evonik stock; see Current market reports.

More news and analyses on Evonik stock.